What are the odds that the company using an adjuvant that could [theoretically] induce #lupus has also just received FDA approval for a breakthrough lupus treatment?

"I will just repeat something I've said before.

Bookmark this tweet. Hydroxychloroquine will be required long term for people that signed up to investigational RNA therapy. The very same people that denigrated it."

Did we all overlook the possible implications of this?

@mentionsThe patent for this "bio-adjuvant" was registered in 2017. Here it is.

Any mRNA candidate using this component therefore did not exist before 2017 and could not have been tested in the clinical arena before then.
patentscope.wipo.int/search/en/deta…

What are the odds that the company using an adjuvant that could [theoretically] induce #lupus has also just received FDA approval for a breakthrough lupus treatment?

I'm so thankful that these companies can find the solutions to all these problems!

According to the inventor Ugur Sahin, the first trials of the RNA vaccine candidates in humans was published in 2017 of 13 patients.

The paper doesn't have a comprehensive methods section so it's not clear whether 12s UTR was used in the vaccine.
nature.com/articles/natur…

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer - NatureThe authors report the first-in-human application of personalized neo-antigen RNA vaccines in patients with melanoma.https://www.nature.com/articles/nature23003

This paper clarifies. In 2019 Sahin publishes the FIRST use of this specific 3'UTR in a mRNA candidate.

In mice. In 2019.

ncbi.nlm.nih.gov/pmc/articles/P….

(the figures show that the 3'UTR was optimised to get uptake in the spleen)

Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library ScreeningSynthetic mRNA has emerged as a powerful tool for the transfer of genetic information, and it is being explored for a variety of therapeutic applications. Many of these applications require prolonged …https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453560/

[NB mtRNR = 12s ribosomal RNA)
It's not really clear why Sahin chose this adjuvant (3'UTR) but what is clear that there were NO human trials using this adjuvant prior to 2019.

Interestingly #lupus patients were effectively excluded from the Pfizer study.

Archived archive.is/upVsX

Addendum... The Moderna 3'UTR uses an alpha-globin RNA. From this patent in 2017.
patents.google.com/patent/WO20172…

I'm sure that the free reign to incorporate miRNAs into the 3'UTR to target different tissues is of no concern. None at all.